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Suppression of the generation of lymphokine-activated killer (LAK)
cells by serum-free supernatants of in vitro maintained tumour cell
lines
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Summary Serum-free supernatants from in vitro maintained gastrointestinal cancer and melanoma cell lines
inhibit the generation of lymphokine (IL-2) activated killer (LAK) cells in a time and dose-related manner.
Concentrations as low as 5% can inhibit the generation of LAK cytotoxicity but inhibition of proliferation is
not observed until higher concentrations are included in the culture system. Inhibition is not observed with
supernatants from a breast cancer cell line nor with supernatants from normal cells. There was complete
concordance between the capacity of the tumour cells themselves to inhibit LAK generation and the presence
of inhibitory activity in the corresponding supernatant. The inhibitory factor(s) is stable after heating to 44
and 56°C. Production of the inhibitory factor(s) is sensitive to metabolic inhibitors and has a molecular
weight greater than 25 kD. The inhibition of LAK cell stimulation by tumour cells may partially explain the
failure of adoptively transferred LAK cells and IL-2 therapy to cause tumour regression in man.
Under certain circumstances lymphocytes derived from the
peripheral blood (PBL) or from tumour-infiltrating leukocyte
(TIL) populations become highly cytotoxic towards tumour
cells on exposure to the T-cell derived lymphokine, inter-
leukin 2 (IL-2) (Grimm et al., 1982; Phillips et al., 1986;
Roberts et al., 1987). In the case of PBL the cytotoxicity is
non-MHC-restricted and the cytotoxic cell precursors are
mainly derived from cells expressing the phenotype of
natural killer cells (Ortaldo et al., 1986; Roberts et al., 1987),
and are termed lymphokine-activated killer (LAK) cells
following exposure to IL-2. In contrast the cytotoxicity
exerted by lymphocytes derived from TIL may be MHC-
restricted and such cells possess T-cell characteristics (Muul
et al., 1987; Whiteside et al., 1988). Adoptive cellular
immunotherapy with either syngeneic LAK or TIL cells
expanded in vitro with IL-2 causes the regression of
established metastases in a wide variety of murine tumour
models (Eberlein et al., 1982; Lafreniere et al., 1985; Mule et
al., 1986b; Rosenberg et al., 1986). Unfortunately this
experience is not paralleled by the clinical application of
such an approach where some 60% of patients with
metastatic disease fail to respond to this therapy (Rosenberg
et al., 1987; West et al., 1987; Topalian et al., 1988).
Similarly, treatment with IL-2 alone appears to be ineffective
(Lotze et al., 1986) despite the fact that many human
tumours are infiltrated by host mononuclear cells which
might become cytotoxic following exposure to IL-2 in vivo
(Svennevig et al., 1984; Cozzolino et al., 1986).
Prompted by the observations that both IL-2 production
and LAK cell generation were impaired with patients with
tumours which had extended beyond local confines (Monson
et al., 1986, 1987), we have previously shown that the
presence of low numbers of some cell-line derived tumour
cells was found to potently inhibit LAK cell generation in
vitro (Guillou et al., 1989). A number of reports have
demonstrated that supernatants derived from tumour cell
lines can inhibit lymphocyte proliferation and cytokine
production (Werkmeister et al., 1980; Meischner et al., 1986;
Ebert et al., 1987; Pommier et al., 1987; Farram et al., 1982;
Hersey et al., 1983). However, the effects of these
supernatants on the generation of cytotoxic responses has
rarely been examined (Cozzolino et al., 1987).
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The present experiments represent an extension of our
previous studies, which have shown that LAK cell
generation can be suppressed by tumour cells in vitro. Our
aim was to determine whether or not such inhibition might
be attributable to tumour-derived soluble suppressor
factorsand to perform a preliminary physicochemical
characterisation of such factors.
Materials and methods
Mononuclear cell separation and culture conditions
Peripheral blood mononuclear cells were isolated from the
heparinised blood of healthy donors by centrifugation on
'lymphoprep' columns (Nyegaard UK Ltd) and depleted of
adherent cells by 2h incubation on plastic Petri dishes
(Nunc). The non-adherent cells were suspended in
RPMI 1640 medium (Gibco) containing gentamicin
(160yugml-1), Fungizone (2.5jugml-1), sodium pyruvate
(2mM), 1% non-essential amino acids, 2-mercaptoethanol
(0.05mM) and 10% mycoplasma-free fetal calf serum.
Lymphocyte culture was performed in 75cm2 upstanding
tissue culture flasks containing a total volume of 20ml and
the final lymphocyte density was 1.5 x 106ml-1.
Recombinant IL-2 (Roche) was added to all cultures at a
concentration of 1,000 units ml-'.
All the experiments described included a control culture to
which no putative suppressor element had been added. The
flasks were incubated at 37°C for four days in a humidified
atmosphere of 5% CO2 in air. At the end of this period the
activated effector cells were harvested, counted and corrected
to a concentration of 5 x 106 viable lymphocytes ml-1 in
complete medium for use in the LAK cytotoxicity assay as
described below.
In some experiments, aliquots of the LAK cells obtained
as described above were seeded into the wells of flat-
bottomed microplates (105 cells per well in five replicates
each in a volume of 0.1 ml). Each well was pulsed with 1 4uCi
3H-thymidine and further incubated at 37°C overnight.
These proliferating lymphocytes were then harvested on to
filter discs and the amount of 3H-thymidine incorporated
measured in a beta-counter.
Tumour cell lines
Studies of the effects of human tumour cell lines or their
supernatants on the generation of LAK cells have been
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performed using the following cell lines. SKBr3 is derived
from a human carcinoma of the breast and is maintained in
Dulbecco's modified minimum essential medium. HT-29,
COL0320 and COL0205 are colorectal cancer cell lines
maintained in RPMI 1640 medium, as is the pancreatic
cancer cell line MiPaCa. The human malignant melanoma
cell line G361 is maintained in McCoy's medium 5A and the
human amniotic cell line, WISH, is maintained in Dulbecco's
modified MEM. The cell lines were all mycoplasma-free as
determined using the Hoechst stain no. 33258. In
experiments in which the tumour cells were added directly to
the LAK generation cultures, they were obtained from the
confluent monolayers after a brief trypsinisation followed by
six washes in complete medium, before re-suspension at a
cell density appropriate to a final lymphocyte:tumour cell
ratio of 50:1, as previously described (Guillou et al., 1989).
Preparation of tumour cell line supernatants
Tumour cell monolayers were grown to confluence and the
medium was discarded. The flasks were gently washed in
serum-free medium so as not to disturb the monolayer but
to remove as much FCS as possible, before reculturing for a
further 24h in serum-free RPMI 1640 medium containing all
the usual additives. This medium was then recovered,
centrifuged to remove any debris and stored at -70°C until
studied as a putative suppressor of LAK cell generation. In
all the experiments to be described supernatants were
obtained from monolayers which were confluent at the time
of harvest and appeared healthy at the end of the 24h
culture period in serum-free medium. Cultures and
supernatants in which the tumour cells had detached from
their monolayer were not used.
In some experiments the effects of metabolic inhibitors on
the release of suppressor factors into the supernatants was
studied. Tumour cells were grown to within 48h of
confluence and the medium replaced with complete medium
containing various concentrations of mitomycin C, actino-
mycin D or cycloheximide (all obtained from Sigma
Chemicals UK). The monolayers were cultured for a further
hour in the presence of these metabolic inhibitors and then
this medium was removed, the cells gently washed and re-
covered with fresh serum-free medium which was harvested
and stored a further 24h later as described above. The final
concentrations of these inhibitors were selected such that
they did not cause gross tumour cell detachment and the
cells were again confluent at the time of supernatant
harvesting. Optimum results were obtained with 0.1pgml-1
of mitomycin C, 0.05 gml-I of actinomycin D and between
1 and 10 pgml-I of cycloheximide. That the inhibitors were
preventing DNA, RNA and protein synthesis was confirmed
in microplate tumour cell monolayers treated identically to
the bulk tumour cell cultures and then pulsed for 12h with
tritiated thymidine, uridine or leucine respectively. The
isotope incorporation into these cultures was diminished but
not eliminated in comparison with that of identical untreated
cultures of the same tumour cell lines.
Temperature sensitivity of suppressive supernatants
Tumour cell line supernatants with suppressive effects on
LAK cell generation were heated at 44, 56 and 70°C for
30min before their addition to LAK generation cultures.
Amicon filtration
Suppressive supernatant samples were enclosed in Amicon
microconcentrator filters of pore diameters corresponding to
molecular weights of 15, 25 and 125 kD for 2h. The
concentrates were then reconstituted to their original
volumes with RPMI 1640 medium before their effects on
LAK cell generation were studied.
Cytotoxicity assay
This was a standard 4h 5"Cr release assay as previously
described (Monson et al., 1987). Doubling dilutions of
5 x 105 effector cells in 0.1 ml complete medium were added
to 104 51Cr-labelled target cells in 0.1ml complete medium
in triplicate round-bottomed microtitre wells. After 4h 100 ul
of the supernatant was harvested from each well and the
radioactivity counted in a gamma-counter. The percentage
specific 51Cr release at each effector:target cell ratio was
calculated as previously described. Data are expressed as
percentage specific 51Cr release at the stated effector:target
cell ratio and also, where appropriate, as lytic units per 107
effector cells. Percentage suppression was calculated on the
basis of the lytic unit figures.
Results
Concordance between tumour cell lines and their
supernatants as suppressors of LAK cell generation in vitro
Table I summarises the results of a series of experiments
whose objective was to identify whether or not the superna-
tants from tumour cell lines were capable of impairing LAK
cell generation in vitro. LAK cells were generated either
alone or in the presence of tumour cells (at a ratio of 1 per
50 lymphocytes) or their supernatants at a final concent-
ration of 20% in culture. These data confirm our previous
report that the presence of tumour cells derived from certain
cell lines (G361, HT-29, COL0205, COL0320, MiPaCa),
but not others (SKBr3 and the non-malignant cell line
WISH), can suppress the generation of LAK cells in vitro.
Moreover, the presence of 20% serum-free supernatant from
the suppressive cell lines was also highly suppressive of LAK
cell generation whereas no suppression was seen with the
supernatants of the non-suppressive cell lines. Similarly,
when supernatants from non-malignant cells (24h cultures of
allogeneic endothelial cells obtained from human umbilical
cord as previously described (Guillou et al., 1989)) were
added at concentrations as high as 20% or more, no
suppression of LAK cell generation was observed. Thus, so
far, we have found concordance between the LAK cell
suppression seen with the tumour cells and that caused by
the presence of their respective supernatants.
Dose and time-related effects of tumour cell supernatants on
LAK cell generation and proliferation
Figure 1 represents the results of one representative experi-
ment in which different concentrations of the tumour cell
supernatant were present in the LAK generation cultures. It
can be seen that concentrations of the COL0205 superna-
tant as low as 5% inhibited LAK cell generation and almost
complete inhibition was observed with concentrations of 10
or 20%. Similar results were obtained with all the other
suppressive cell line supernatants, maximum suppression
being obtained with concentrations of 20%. In contrast,
concentrations of supernatants from the non-suppressive cell
lines had no effect on LAK cell generation at concentrations
as high as 50% of the total culture volume. Figure 2 shows
the effects of the COL0205 supernatant on the proliferation
of these same IL-2 activated lymphocytes as assessed by the
uptake of 3H-thymidine. Inhibition of lymphocyte prolife-
ration was significantly diminished only at supernatant con-
centrations of 10% or more.
In Figure 3 it can be seen that the inhibitory effects of the
tumour cell line supernatants were also temporally related.
Significant inhibition of LAK generation occurred only when
the supernatant was present within the first 48 h of culture,
there being no suppression when the addition of the superna-
tant was delayed until the third or fourth days of culture.
Effects of tumour cell supernatants on cytotoxic effector cell
function in vitro
The data shown in Figure 3 suggested that suppressive
tumour cell supernatants have no effect on LAK cytotoxicityLAK CELL SUPPRESSION 517
Table I Effects of tumour cell lines and their supernatants on LAK cell generation
Percentage cytotoxicity
Effector cell Target 50:1 12:1 LU % Suppression
Exp. I
LAK alone
LAK/G361 cells
LAK/20%G361Supa
LAK/SKBr3 cells
LAK/20%SKBr3Supa
LAK/HT29 cells
LAK/20%HT29Supa
Exp. 2
LAK alone
LAK/COL0320 cells
LAK/20%COL0320 Supa
LAK/SKBr3 cells
LAK/20%SKBrSupa
Exp. 3
LAK alone
LAK/G361 cells
LAK/20%G361Supa
LAK/SKBr3 cells
LAK/200%SKBr3Supa
LAK/MiPaCa cells
LAK/20%MiPaCaSupa
Exp. 4
LAK alone
LAK/G361 cells
LAK/20%,G361Supa
LAK/WISH cells
LAK/20%WISHSupa
Exp. 5
LAK alone
LAK/COLO205 cells
LAK/20%COL0205Supa
LAK/SKBr3 cells
LAK/20%SKBr3Supa
Exp. 6
LAK alone
LAK/20%HT29Supa
LAK/20%Endothelial cell Supa
Exp. 7
LAK alone
LAK/20%G361Supa
LAK/20%Endothelial cell Supa
G361
G361
G361
G361
G361
G361
G361
COL0320
COL0320
COL0320
COL0320
COL0320
G361
G361
G361
G361
G361
G361
G361
SKBr3
SKBr3
SKBr3
SKBr3
SKBr3
SKBr3
SKBr3
SKBr3
SKBr3
SKBr3
SKBr3
SKBr3
SKBr3
COL0320
COL0320
COL0320
41.3
14.6
4.2
40.8
38.5
9.3
5.3
15.7
6.4
0.3
15.0
17.4
2.8
3.0
35.4 19.3
23.2 9.9
25.6 11.5
36.4 19.0
35.8 18.0
84.7 49.1
20.6 6.1
13.3 4.0
85.6 49.1
81.7 43.3
28.6 10.3
48.9 6.9
45.8 25.9
16.4 8.4
11.4 6.7
47.7 24.7
53.9 31.8
75.5 35.7
27.7 8.8
7.9 0.9
74.8 39.5
73.8 34.3
24.8 7.1
1.9 0.4
25.01 6.0
45.8
11.4
47.7
34.7
4.3
0.005
34.0
28.0
0.002
0.001
25.3
5.9
9.6
24.3
22.8
163.0
2.0
0.23
137.1
136.3
9.6
12.8
52.0
0.7
0.03
52.1
72.8
86.3
11.01
0.004
99.3
88.9
8.3
0.001
8.8
25.9 52
6.7 0.03
25.7 52.1
87.6
99.9
2.0
19.3
99.9
99.9
76.7
62.1
3.9
9.9
98.8
99.9
15.9
16.4
94.1
92.1
98.7
99.9
0.2
-40.0
87.2
99.99
- 15.1
-3.0
99.9
-5.0
99.9
-0.2
aTumour cell and endothelial cell supernatants were serum-free and collected after 24h of cell culture. These were added to LAK cell generation cultures at a final concentration of 20%. Tumour cells were added to LAK generation cultures at a ratio of one tumour cell per 50 lymphocytes. LAK cytotoxicity was measured 4 days later and the data are expressed as percentage specific 5tCr release from the indicated target cell at the effector:target cell ratios shown. Lytic units were calculated from data obtained at all the effector:target cell ratios and percentage suppression calculated by comparison with the lytic units measured in the corresponding control cultures containing no putative suppressor element (designated 'LAK alone').
when added to the LAK generation cultures late in the
culture period and thus do not directly impair the binding,
lethal hit or lytic phases of cellular cytotoxicity. In order to
confirm this we conducted experiments in which tumour cell
supernatants were incorporated into the cytotoxicity assay
directly and these data are shown in Table II. It can be seen
that even at concentrations as high as 40% little inhibition
of LAK cell cytotoxicity was caused by the presence of the
tumour cell supernatants.
Temperature sensitivity of the suppressive supernatants
The suppression observed was insensitive to heating at 44 or
56°C for 30min but was eliminated by heating to 70°C for
the same time period (Table III).
Effects of Amiconfiltration on the suppression of LAK cell
generation
Table IV summarises the results of several experiments in
which the suppressive supernatants were subjected to
Amicon filtration, reconstituted to their original volumes and
incorporated in the LAK generation cultures at a final
concentration of 20%. Loss of suppressive activity was seen
only when the supernatant was subjected to filtration
through a microconcentrater of pore size corresponding to a
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Figure 1 Effects of different concentrations of serum-free super-
natant from COLO 205 colorectal cancer cell line on the gene-
ration of lymphokine-activated killer cells in vitro (mean
percentage specific 5'Cr release +s.d.).
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Figure 2 Effects of COLO 205 supernatant on IL-2 stimulated
3H-thymidine uptake.
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Figure 3 Relationship between the suppression of LAK cell
generation by G361 melanoma cell line supernatant and time of
addition of the supernatant. For reasons of clarity, the data for
cultures to which no supernatant was added are omitted, but the
cytotoxicity was identical to that of cultures to which superna-
tants were added on the day of assay, i.e. day 4.
Table II Effects of tumour cell supernatants on the cytotoxicity
assay in vitro
Conc. supernate in
51Cr-release assay
Source of supernatant 5% 10% 20% 40%
Fresh RPMI 1640 29.Oa 29.0 27.5 25.3
COL0320 27.0 25.1 22.4 19.9
HT-29 27.0 25.1 24.7 21.1
SKBr3 26.9 25.2 23.6 22.7
COL0205 27.3 27.4 25.7 26.5
G361 29.5 27.5 24.7 21.1
LAK cells were generated from PBMC in the standard manner
and then tested in the "Cr-release assay at an effector:target cell
ratio of 50:1. Serum-free medium from each of the tumour cell lines
described was added directly to the 51Cr-release assay at the
concentrations indicated; aFigures refer to the percentage specific
5"Cr-release from 5"Cr-labelled SKBr3 target cells at a single
effector:target ratio of 50:1. Specific 5"Cr-release at 50:1 in the
absence of supernatant was 29.0%.
Table III Thermosensitivity of tumour-derived suppressor factor
% Cytotoxicity
Temperature Target 50:1 12:1 LU % Suppression
Control (LAK alone) SKBr3 32.5 12.4 17.8
Untreated supernate SKBr3 1.7 1.4 <0.001 99.99
44°C for 30 min SKBr3 1.8 0.03 <0.001 99.99
56°C for 30 min SKBr3 1.71 0.4 <0.001 99.99
70°C for 30 min SKBr3 30.3 11.8 14.7 17.4
Serum-free supernatant from G361 melanoma was heated to the
temperatures recorded and added to LAK generation cultures at a final
concentration of 20%. LAK cytotoxicity was measured against SKBr3 cells
after four days in culture and is expressed as % specific "Cr release at the
effector: target cell ratios shown as well as lytic units. Percentage suppression
was calculated as described in the legend to Table I.
Table IV Effects of Amicon filtration on tumour-derived suppressor factor
% Cytotoxicity
Filter pore diameter Target 50:1 12:1 LU % Suppression
Control (LAK alone) SKBr3 67.8 34.6 85.4
Unfiltered supernate SKBr3 5.4 0.5 0.01 99.99
15 kD filter SKBr3 2.8 0.3 0.01 99.99
25kD filter SKBr3 7.7 1.0 0.1 99.9
125kD filter SKBr3 69.5 35.0 86.8 -1.6
Serum-free G361 supernatant was subjected to Amicon filtration with filters
of differing pore diameters. The residual supernatant was reconstituted to the
original volume with RPMI 1640 medium and added to LAK generation
cultures at a concentration of 20%. LAK cytotoxicity was measured 4 days
later and the data expressed as described in Table I.
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Figure 4 Effects of metabolic inhibitors on the suppressive
effects of tumour cell line supernatants on LAK cell generation.
molecular weight of 125kD, there being no loss of activity
with filters of 15 or 25 kD porosity.
Effects of metabolic inhibitors on the production of
suppressor factors in tumour cell supernatants
The inhibition of protein synthesis by cycloheximide was
markedly inhibitory towards the production of the suppres-
sor factor (Figure 4). The suppression caused by the tumour
cell line-derived supernatants was almost completely inhi-
bited by treatment of the tumour cells with 10 gmlPl of
cycloheximide. In addition the inhibition of DNA and RNA
synthesis (as assessed by the uptake of radiolabelled thymi-
dine and uridine respectively by the tumour cells) was also
effective in impairing the production of the LAK cell
suppressor factors present in the supernatants derived from
confluent tumour cell lines.
Discussion
The administration of IL-2 activated lymphocytes as thera-
peutic agents for human cancer currently meets with only
limited success and cannot compare with the results accom-
plished with the same approach in experimental animals.
However, in making this comparison differences between the
murine and human application of adoptive cellular immuno-
therapy require consideration. In the murine studies acti-
vated lymphocytes are derived from normal, non-tumour-
bearing syngeneic animals, whereas in clinical application the
activated cells are of course autologous to the patient. If
tumour-mediated suppression of lymphocyte activation does
occur in vivo, the cytolytic efficacy of autologous lympho-
cytes might be less than that of lymphocytes derived from
healthy individuals, and we have already shown this to be
the case (Monson et al., 1986, 1987). Furthermore, both
clinically and experimentally, the administration of IL-2
alone (without adoptive cellular immunotherapy) fails to
accomplish tumour regression suggesting that the suppressive
mechanisms operative in man also exist in murine models
(Mule et al., 1986a; Salup et al., 1986; Rosenberg et al.,
1987). We have attempted to investigate the role of the
tumour cell (as opposed to host factors such as suppressor
cells) in this context.
The experiments reported in this paper confirm and extend
our previous report that cells derived from some con-
tinuously growing tumour cell lines impair the generation of
lymphokine-activated killer cells in vitro. Thus cells derived
from cultures of human malignant melanoma, colorectal and
pancreatic cancer, but not from the breast cancer cell line
SKBr3 nor from WISH cells, can inhibit LAK cell gene-
ration in vitro. Moreover, in the present investigations we
have found that serum-free supernatants from the suppres-
sive, but not from the non-suppressive, cell lines can also
pot ntly inhibit LAK cell generation in a dose and time-
related manner. The concordance between the suppression
c i,sed by the tumour cells and that caused by their corres-
ponding supernatants suggests that the inhibition is mediated
via the release of a soluble factor(s) from the tumour cells.
The time course of the inhibition obtained with the superna-
tants is identical with that we have previously reported for
the inhibition of LAK cell function by the tumour cells
themselves, i.e. that the putative suppressor factor(s) must be
present within the first 48 h of the initiation of culture
(Guillou et al., 1988). Further studies are required to deter-
mine whether other cell lines of non-malignant or malignant
origin cause similar effects.
The suppressor factor(s) does not directly inhibit cytotoxi-
city at the level of the effector cell as evidenced by the data
shown in Table II. Furthermore in experiments not shown
here, we have been unable to render the tumour target cells
resistant to cytotoxicity by prior culture in the supernatant.
Thus the tumour-derived factors do not appear to work in a
manner analogous to that of the protective effects which
interferons are able to exert on natural killer and LAK cell
tumour targets (De Fries et al., 1988; Yeoman et al., 1988).
That prior treatment of the tumour cells with inhibitors of
DNA, RNA and protein synthesis eliminates the inhibition
of LAK cell induction observed in the presence of the
tumour cell supernatants suggests that the suppressor factors
are proteins coded for in the tumour genome. However,
interference by virally encoded proteins cannot be excluded.
Indeed, one such viral peptide, the retroviral envelope pro-
tein P15E, has been implicated in the suppression of lympho-
cyte proliferation (Snyderman et al., 1984). P15E perturbs
monocyte function and directly inhibits T-lymphocyte proli-
feration (Harrell et al., 1986; Copelan et al., 1983). Although
P15E is normally only found in the envelope of lympho-
tropic or leukaemic viruses this peptide has been detected in
murine B16 melanoma and is also expressed in lectin-
activated lymphoblasts (Cianciolo et al., 1983, 1984). It has
been shown that monoclonal antibodies to P15E can prevent
the suppressive effects of certain bovine tumour extracts on
delayed hypersensitivity in vivo (Nelson et al., 1985). As
observed with the tumour supernatants reported herein, the
suppressive effects of P15E are resistant to heating at 56°C.
In contrast, our preliminary crude estimate of the molecular
weight of the factor(s) present in our supernatants indicate
something in excess of 25kD rather than the 15 kD of P15E.
More directly, however, although a synthetic peptide
homologous to P1SE inhibits both spontaneous and
interferon-boosted human NK activity, it has not been found
to impair the activation of NK cells by IL-2 (Harris et al.,
1987).
A number of alternative candidate molecules for the
supernatant suppressor factor described in our studies exist
in the literature. Putnam & Roth (1985) have described a
heat-stable, acid-labile glycoprotein derived from murine
melanoma which can inhibit proliferative responses to lectins
and IL-2. However, the molecular weight of this factor was
only of the order of 10-12kD but was distinct from P15E.
Pommier et al. (1987) and Ebert et al. (1987) have described
a factor present in conditioned medium from HT-29 cells
which was able to inhibit IL-2 production and lymphocyte
proliferation and whose effects could not be prevented by
the addition of further IL-2. The molecular weight of their
factor was around 56kD and because our factor(s) also
appear to inhibit lymphocyte proliferation at higher concent-
rations the two may be identical. In our experiments the
induction of LAK cell cytotoxicity was impaired at lower
concentrations of supernatant than those required to inhibit
proliferation, in keeping with previous suggestions that the in
vitro induction of LAK cells is not dependent on DNA
synthesis (Malkovsky et al., 1987). This antiproliferative
effect may have some in vivo significance, however, since
experimentally IL-2 stimulates the proliferation of adoptively
transferred LAK cells, the proliferation apparently being
essential for therapeutic efficacy (Ettinghausen et al., 1985).520 P.J. GUILLOU et al.
Mieschner et al. (1986) have also reported that gastro-
intestinal cancer cells and their products can also repress the
proliferation of tumour infiltrating lymphocytes. Tumour cell
lines derived from a variety of colorectal carcinomas appear
to secrete both alpha and beta transforming growth factors
(Coffey et al., 1986; Hanauske et al., 1987), the latter having
recently been described as a potent inhibitor of NK cell
activity and murine LAK cell induction (Rook et al., 1986).
These growth factors might therefore represent potential
candidates for the inhibitory substances present in our
tumour cell supernatants.
Whiteside et al. (1988) have experienced difficulty in
generating proliferating lymphocytes from TIL extracted
from metastatic head and neck and colorectal cancers. Even
when so generated (following a lag period of some 30-40
days) such proliferating lymphocytes exert little or no cytoly-
tic activity, suggesting that the suppressive effects seen in our
in vitro experiments may also be operative in vivo. It is
evident that caution must be exercised in extrapolating the
results of these in vitro experiments to clinical in vivo
circumstances. Nevertheless, it is tempting to speculate that
the experiments we have described may lead to at least a
partial explanation of the failure of IL-2 therapy to cause
durable remission in patients suffering from advanced malig-
nant disease. The relationship of the factors which we have
observed to those described by others remains to be eluci-
dated and we are currently attempting to characterise them
in greater detail. However, if these studies succeed in demon-
strating that such factors have in vivo relevance then their
characterisation may result in the development of further
strategies aimed at augmenting the clinical response rates to
immunotherapy.
References
CIANCIOLO, G.J., LOSTROM, M.E., TAM, M. & SNYDERMAN, R.
(1983). Murine malignant cells synthesize a 19,000 dalton protein
which is physicochemically and antigenically related to the
immunosuppressive retroviral protein, pl5E. J. Exp. Med., 158,
885.
CIANCIOLO, G.J., PHIPPS, D. & SNYDERMAN, R. (1984). Human
malignant and mitogen transformed cells contain retroviral pl5E
related antigen. J. Exp. Med., 159, 964.
COFFEY, R.J., SHIPLEY, G.D. & MOSES, H.L. (1986). Production of
transforming growth factors by human colon cancer cell lines.
Cancer Res., 46, 1164.
COPELAN, E.A., RINEHART, J.J., LEWIS, M., MATHES, L., OLSEN, R.
& SAGONE, A. (1983). The mechanism of retrovirus suppression
of human T cell proliferation in vitro. J. Immunol., 131, 2017.
COZZOLINO, F., TORCIA, M., CASTIGLI, E. & 7 others (1986).
Presence of activated T-cells with a T8+, Ml+, Leu7+ surface
phenotype in invaded lymph nodes from patients with solid
tumours. JNCI, 77, 637.
COZZOLINO, F., TORCIA, M., CAROSSINO, A.M. & 7 others (1987).
Characterization of cells from invaded lymph nodes in patients
with solid tumours. Lymphokine requirement for tumour-specific
lymphoproliferative response. J. Exp. Med., 166, 303.
DE FRIES, R.U. & GOLUB, S.H. (1988). Characteristics and mecha-
nism of IFN-gamma-induced protection of human tumor cells
from lysis by lymphokine-activated killer cells. J. Immunol., 140,
3686.
EBERLEIN, T.J., ROSENSTEIN, M.R. & ROSENBERG, S.A. (1982).
Regression of a syngeneic solid tumor by systemic transfer of
lymphoid cells expanded in interleukin 2 in mice. J. Exp. Med.,
156, 385.
EBERT, E.C., ROBERTS, A.I., O'CONNELL, S.M., ROBERTSON, F.M. &
NAGASE, H. (1987). Characterization of an immunosuppressive
factor derived from human colon cancer cells. J. Immunol., 138,
2161.
ETTINGHAUSEN, S.E., LIPFORD, E.H., MULE, J.J. & ROSENBERG,
S.A. (1985). Recombinant interleukin 2 stimulates in vivo prolife-
ration of adoptively transferred lymphokine-activated killer cells.
J. Immunol., 135, 3899.
FARRAM, E., NELSON, M., NELSON, D.S. & MOON, D.K. (1982).
Inhibition of cytokine production by a tumor cell product.
Immunology, 46, 603.
GRIMM, E.A., MAZUMDER, A., ZHANG, H.Z. & ROSENBERG, S.A.
(1982). Lymphokine-activated killer cell phenomenon. Lysis of
natural killer-resistant fresh solid tumor cells by interleukin 2-
activated autologous human peripheral blood lymphocytes. J.
Exp. Med., 155, 1823.
GUILLOU, P.J., SEDMAN, P.C. & RAMSDEN, C.W. (1989). The inhibi-
tion of lymphokine-activated killer cell generation by cultured
tumour cell lines in vitro. Cancer Immunol. Immunother., 28, 43.
HANAUSKE, A.R., BUCHOK, J., SCHEITHAUER, W. & VON HOFF,
D.D. (1987). Human colon cancer cells lines secrete alpha-TGF-
like activity. Br. J. Cancer, 55, 57.
HARRELL, R.A., CIANCIOLO, G.J., COPELAND, T.D., OROSZLAN, S.
& SNYDERMAN, R. (1986). Suppression of the respiratory burst
of human monocytes by a synthetic peptide homologous to the
envelope proteins of human and animal retroviruses.
J. Immunol., 136, 3517.
HARRIS, D.T., CIANCIOLO, G.J., SNYDERMAN, R., ARGOV, S. &
KOREN, H.S. (1987). Inhibition of human natural killer cell
activity by a synthetic peptide homologous to a conserved region
in the retroviral protein pl5E. J. Immunol., 138, 889.
HERSEY, P., BINDON, C., CZERIECKI, M., SPURLING, M., WASS, J.
& McCARTHY, W.H. (1983). Inhibition of interleukin 2 produc-
tion by factors released from tumor cells. J. Immunol., 131, 2837.
LAFRENIERE, R. & ROSENBERG, S.A. (1985). Successful immuno-
therapy of murine experimental hepatic metastases with
lymphokine-activated killer cells and recombinant interleukin 2.
Cancer Res., 45, 3735.
LOTZE, M.T., MATORY, Y.L., RAYNER, A.A. & 4 others (1986).
Clinical effects and toxicity of interleukin-2 in patients with
cancer. Cancer, 58, 2772.
MALKOVSKY, M., JIRA, M., MADAR, J., MALKOVSKA, V.,
LOVELAND, V. & ASHERSON, G.L. (1987). Generation of
lymphokine-activated killer cells does not require DNA synthesis.
Immunology, 60, 471.
MIESCHNER, S., WHITESIDE, T.L., CAREEL, S. & VON FLIEDNER, V.
(1986). Functional properties of tumor-infiltrating and blood
lymphocytes in patients with solid tumours: effects of tumour
cells and their supernatants on proliferative responses of lympho-
cytes. J. Immunol., 136, 1899.
MONSON, J.R.T., RAMSDEN, C.W. & GUILLOU, P.J. (1986).
Decreased interleukin-2 production in patients with gastro-
intestinal cancer. Br. J. Surg., 73, 483.
MONSON, J.R.T., RAMSDEN, C.W., GILES, G.R., BRENNAN, T.G. &
GUILLOU, P.J. (1987). Lymphokine-activated killer (LAK) cells
in patients with gastrointestinal cancer. Gut, 28, 1420.
MULE, J.J., ETTINGHAUSEN, S.E., SPIESS, P.J. & ROSENBERG, S.A.
(1986a). Antitumor efficacy of lymphokine-activated killer cells
and interleukin 2 in vivo: survival benefit and mechanisms of
tumor escape in mice undergoing immunotherapy. Cancer Res.,
46, 676.
MULE, J.J., YANG, J., SHU, S. & ROSENBERG, S.A. (1986b). The
antitumor efficacy of lymphokine-activated killer cells and
recombinant interleukin 2 in vivo: direct correlation between
reduction of established metastases and cytolytic activity of
lymphokine-activated killer cells. J. Immunol., 136, 3899.
MUUL, L.M., SPIESS, P.J., DIRECTOR, E.P. & ROSENBERG, S.A.
(1987). Identification of specific cytolytic immune responses
against autologous tumor in humans bearing malignant mela-
noma. J. Immunol., 138, 989.
NELSON, M., NELSON, D.S., SPRADBROW, P.B. & 4 others (1985).
Successful tumour immunotherapy: possible role of antibodies to
anti-inflammatory factors produced by neoplasms. Clin. Exp.
Immunol., 61, 109.
ORTALDO, J.R., MASON, A. & OVERTON, R. (1986). Lymphokine-
activated killer cells. Analysis of progenitors and effectors. J.
Exp. Med., 164, 1193.
PHILLIPS, J.H. & LANIER, L.L. (1986). Dissection of the lymphokine-
activated killer cell phenomenon. Relative contribution of peri-
pheral blood natural killer cells, and T lymphocytes to cytolysis.
J. Exp. Med., 164, 814.LAK CELL SUPPRESSION 521
POMMIER, G.J., GARROUSTE, F.L., BETrETINI, D., CULOUSCOU,
J.M. & REMACLE-BONNET, M.M. (1987). In vivo delayed rejection
of tumors and inhibition of delayed-type hypersensitivity by HT-
29 human colonic adenocarcinoma cell line. Cancer Immunol.
Immunother., 24, 225.
PUTNAM, J.B. & ROTH, J.A. (1985). Identification and characteriza-
tion of a tumor-derived immunosuppressive glycoprotein from
murine melanoma K-1735. Cancer Immunol. Immunother., 19, 90.
ROBERTS, K., LOTZE, M.T. & ROSENBERG, S.A. (1987). Separation
and functional studies of the human lymphokine-activated killer
cell. Cancer Res., 47, 4366.
ROOK, A.H., KEHRL, J.H., WAKEFIELD, L.M. & 5 others (1986).
Effects of transforming growth factor B on the functions of
natural killer cells: depressed cytolytic activity and blunting of
interferon responsiveness. J. Immunol., 136, 3916.
ROSENBERG, S.A., SPIESS, P. & LAFRENIERE, R. (1986). A new
approach to the adoptive immunotherapy of cancer with tumor-
infiltrting lymphocytes. Science, 233, 1318.
ROSENBERG, S.A., LOTZE, M.T., MUUL, L.M. & 10 others (1987). A
progress report on the treatment of 157 patients with advanced
cancer using lymphokine-activated killer cells and interleukin-2
or high dose interleukin-2 alone. N. Engl. J. Med., 316, 889.
SALUP, R.R. & WILTROUTR, H. (1986). Adjuvant immunotherapy of
established murine renal cancer by interleukin 2-stimulated cyto-
toxic lymphocytes. Cancer Res., 46, 3358.
SNYDERMAN, R. & CIANCIOLO, G.J. (1984). Immunosuppressive
activity of the retroviral envelope protein pl5E and its possible
relationship to neoplasia. Immunol. Today, 5, 240.
SVENNEVIG, J.L., LUNDE, O.C., HOLTER, J. & BJORGSVIK, D.
(1984). Lymphoid infiltration and prognosis in colorectal carci-
noma. Br. J. Cancer, 49, 375.
TOPALIAN, S.L., SOLOMON, D., AVIS, F.P. & 9 others (1988).
Immunotherapy of patients with advanced cancer using tumor-
infiltrating lymphocytes and recombinant interleukin-2: a pilot
study. J. Clin. Oncol., 6, 839.
WERKMEISTER, J., ZAUNDERS, W., McCARTHY, W. & HERSEY, P.
(1980). Characterization of an inhibitor of cell division released
in tumour cell cultures. Clin. Exp. Immunol., 41, 487.
WEST, W.H., TAUER, K.H., YANNELLI, J.R.. & 4 others (1987).
Constant-infusion recombinant interleukin-2 in adoptive im-
munotherapy of advanced cancer. N. Engl. J. Med., 316, 898.
WHITESIDE, T.L., HEO, D.S., TAKAGI, S., JOHNSON, J.T., IWATSUKI,
S. & HERBERMAN, R.B. (1988). Cytolytic antitumor effector cells
in long term cultures of human tumor-infiltrating lymphocytes in
recombinant interleukin 2. Cancer Immunol. Immunother., 26, 1.
YEOMAN, H. & ROBINS, R.A. (1988). The effect of interferon-gamma
treatment of rat tumor cells on their susceptibility to natural
killer cell, macrophage and cytotoxic T-cell killing. Immunology,
63, 291.